Semin Respir Crit Care Med 2016; 37(05): 716-726
DOI: 10.1055/s-0036-1592113
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Radiation Therapy for Stage I Nonoperable or Medically Inoperable Lung Cancer

Amar U. Kishan
1   Department of Radiation Oncology, University of California, Los Angeles, California
,
Percy Lee
1   Department of Radiation Oncology, University of California, Los Angeles, California
› Author Affiliations
Further Information

Publication History

Publication Date:
12 October 2016 (online)

Abstract

Non-small cell lung cancer (NSCLC) is the second most common solid malignancy in the United States of America, and the leading cause of cancer-related mortality. Nearly 15% of patients present with early-stage disease, for which the standard of care is lobectomy. However, the median age at diagnosis ranges from 65 to 74 years, and many patients have significant comorbidities that preclude surgical treatment. Previously, the standard of care for these patients was definitive radiotherapy (RT) with conventional fractionation (i.e., 1.8–2 Gy fractions delivered over 30–33 treatment sessions). Local control following this treatment ranged from 30 to 70%, and overall survival was poor at 15 to 30%. Over the years, advances in RT technology, imaging, planning, and RT delivery platforms have allowed the advent of stereotactic body radiotherapy (SBRT), in which large doses of radiation are delivered to a given target volume over a small number of fractions, while sparing adjacent organs-at-risk. Based on extremely promising local control rates in prospective studies, SBRT has quickly become the standard of care for treating early-stage NSCLC in medically inoperable patients. Here, we review the historical context of RT for NSCLC, provide a brief of overview of the radiobiological rationale for and the medical physics aspects of SBRT, and review the clinical evidence for its efficacy. We then briefly discuss future directions, including identifying the optimal dose/fractionation regimen and exploring the treatment of centrally-located tumors. Finally, we discuss the available data regarding the use of SBRT for medically operable patients.

 
  • References

  • 1 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63 (1) 11-30
  • 2 Society AC. Cancer Facts & Figures 2015. American Cancer Society 2015. Available from: http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf . Accessed on November 1, 2015
  • 3 Institute NC. SEER Stat Fact Sheets: Lung and Bronchus Cancer. Available from: http://seer.cancer.gov/statfacts/html/lungb.html . Accessed on November 1, 2015
  • 4 Aberle DR, Adams AM, Berg CD , et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365 (5) 395-409
  • 5 Humphrey LL, Deffebach M, Pappas M , et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US preventive services task force recommendation. Ann Intern Med 2013; 159 (6) 411-420
  • 6 Al-Shahrabani F, Vallböhmer D, Angenendt S, Knoefel WT. Surgical strategies in the therapy of non-small cell lung cancer. World J Clin Oncol 2014; 5 (4) 595-603
  • 7 Dominioni L, Imperatori A, Rovera F, Ochetti A, Torrigiotti G, Paolucci M. Stage I nonsmall cell lung carcinoma: analysis of survival and implications for screening. Cancer 2000; 89 (11, Suppl): 2334-2344
  • 8 Ginsberg RJ, Rubinstein LV ; Lung Cancer Study Group. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Ann Thorac Surg 1995; 60 (3) 615-622 , discussion 622–623
  • 9 Padda SK, Burt BM, Trakul N, Wakelee HA. Early-stage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy. Semin Oncol 2014; 41 (1) 40-56
  • 10 Cykert S, Dilworth-Anderson P, Monroe MH , et al. Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer. JAMA 2010; 303 (23) 2368-2376
  • 11 Stanzani F, Paisani DdeM, Oliveira Ad, Souza RC, Perfeito JA, Faresin SM. Morbidity, mortality, and categorization of the risk of perioperative complications in lung cancer patients. J Bras Pneumol 2014; 40 (1) 21-29
  • 12 Network NCC. Non-Small Cell Lung Cancer 2016. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf . Accessed on November 1, 2015
  • 13 Smart J, Hilton G. Radiotherapy of cancer of the lung; results in a selected group of cases. Lancet 1956; 270 (6928) 880-881
  • 14 Hilton G. The present position relating to cancer of the lung. Results with radiotherapy alone. Thorax 1960; 15: 17-18
  • 15 Bromley LL, Szur L. Combined radiotherapy and resection for carcinoma of the bronchus; experiences with 66 patients. Lancet 1955; 269 (6897) 937-941
  • 16 Morrison RD, Deeley TJ, Cleland WP. The treatment of carcinoma of the bronchus: a clinical trial to compare surgery and supervoltage radiotherapy. Lancet 1963; 281 (7283) 683-684
  • 17 Qiao X, Tullgren O, Lax I, Sirzén F, Lewensohn R. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer 2003; 41 (1) 1-11
  • 18 Hall EJ, Giaccia AJ. Radiobiology for the Radiologist. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011
  • 19 Dosoretz DE, Katin MJ, Blitzer PH , et al. Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies. Int J Radiat Oncol Biol Phys 1992; 24 (1) 3-9
  • 20 Slotman BJ, Njo KH, Karim AB. Curative radiotherapy for technically operable stage I nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1994; 29 (1) 33-37
  • 21 Onishi H, Shirato H, Nagata Y , et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007; 2 (7) (Suppl. 03) S94-S100
  • 22 Onishi H, Araki T, Shirato H , et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004; 101 (7) 1623-1631
  • 23 Zhang J, Yang F, Li B , et al. Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis. Int J Radiat Oncol Biol Phys 2011; 81 (4) e305-e316
  • 24 Mehta N, King CR, Agazaryan N, Steinberg M, Hua A, Lee P. Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: a pooled analysis of biological equivalent dose and local control. Pract Radiat Oncol 2012; 2 (4) 288-295
  • 25 Kestin L, Grills I, Guckenberger M , et al; Elekta Lung Research Group. Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance. Radiother Oncol 2014; 110 (3) 499-504
  • 26 Koshy M, Malik R, Weichselbaum RR, Sher DJ. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2015; 91 (2) 344-350
  • 27 Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70 (3) 847-852
  • 28 Brown JM, Carlson DJ, Brenner DJ. The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?. Int J Radiat Oncol Biol Phys 2014; 88 (2) 254-262
  • 29 Garcia-Barros M, Paris F, Cordon-Cardo C , et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300 (5622) 1155-1159
  • 30 Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res 2012; 177 (3) 311-327
  • 31 Gandhi SJ, Minn AJ, Vonderheide RH, Wherry EJ, Hahn SM, Maity A. Awakening the immune system with radiation: optimal dose and fractionation. Cancer Lett 2015; 368 (2) 185-190
  • 32 Twyman-Saint Victor C, Rech AJ, Maity A , et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015; 520 (7547) 373-377
  • 33 Leksell L. The stereotaxic method and radiosurgery of the brain. Acta Chir Scand 1951; 102 (4) 316-319
  • 34 Kondziolka D, Flickinger JC, Niranjan A, Lunsford LD. Trends and importance of radiosurgery for the development of functional neurosurgery. Surg Neurol Int 2012; 3 (1) (Suppl. 01) S3-S9
  • 35 Lax I, Blomgren H, Näslund I, Svanström R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 1994; 33 (6) 677-683
  • 36 Blomgren H, Lax I, Näslund I, Svanström R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 1995; 34 (6) 861-870
  • 37 Slotman BJ, Antonisse IE, Njo KH. Limited field irradiation in early stage (T1-2N0) non-small cell lung cancer. Radiother Oncol 1996; 41 (1) 41-44
  • 38 Nagata Y, Negoro Y, Aoki T , et al. Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2002; 52 (4) 1041-1046
  • 39 Uematsu M, Shioda A, Suda A , et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001; 51 (3) 666-670
  • 40 Fukumoto S, Shirato H, Shimzu S , et al. Small-volume image-guided radiotherapy using hypofractionated, coplanar, and noncoplanar multiple fields for patients with inoperable Stage I nonsmall cell lung carcinomas. Cancer 2002; 95 (7) 1546-1553
  • 41 Lee SW, Choi EK, Park HJ , et al. Stereotactic body frame based fractionated radiosurgery on consecutive days for primary or metastatic tumors in the lung. Lung Cancer 2003; 40 (3) 309-315
  • 42 Fritz P, Kraus HJ, Mühlnickel W , et al. Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases. Radiat Oncol 2006; 1: 30
  • 43 Hof H, Herfarth KK, Münter M , et al. Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2003; 56 (2) 335-341
  • 44 McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys 2005; 63 (4) 1010-1015
  • 45 Le QT, Loo BW, Ho A , et al. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol 2006; 1 (8) 802-809
  • 46 Kothary N, Heit JJ, Louie JD , et al. Safety and efficacy of percutaneous fiducial marker implantation for image-guided radiation therapy. J Vasc Interv Radiol 2009; 20 (2) 235-239
  • 47 Shen Y, Zhang H, Wang J , et al. Hypofractionated radiotherapy for lung tumors with online cone beam CT guidance and active breathing control. Radiat Oncol 2010; 5: 19
  • 48 Jang SS, Huh GJ, Park SY, Yang PS, Cho EY. The impact of respiratory gating on lung dosimetry in stereotactic body radiotherapy for lung cancer. Phys Med 2014; 30 (6) 682-689
  • 49 Underberg RW, Lagerwaard FJ, Cuijpers JP, Slotman BJ, van Sörnsen de Koste JR, Senan S. Four-dimensional CT scans for treatment planning in stereotactic radiotherapy for stage I lung cancer. Int J Radiat Oncol Biol Phys 2004; 60 (4) 1283-1290
  • 50 Wang L, Hayes S, Paskalev K , et al. Dosimetric comparison of stereotactic body radiotherapy using 4D CT and multiphase CT images for treatment planning of lung cancer: evaluation of the impact on daily dose coverage. Radiother Oncol 2009; 91 (3) 314-324
  • 51 Yin FF, Wang Z, Yoo S , et al. Integration of cone-beam CT in stereotactic body radiation therapy. Technol Cancer Res Treat 2008; 7 (2) 133-139
  • 52 Timmerman RD, Forster KM, Chinsoo Cho L. Extracranial stereotactic radiation delivery. Semin Radiat Oncol 2005; 15 (3) 202-207
  • 53 Rauschenbach BM, Mackowiak L, Malhotra HK. A dosimetric comparison of three-dimensional conformal radiotherapy, volumetric-modulated arc therapy, and dynamic conformal arc therapy in the treatment of non-small cell lung cancer using stereotactic body radiotherapy. J Appl Clin Med Phys 2014; 15 (5) 4898
  • 54 Timmerman R, Papiez L, McGarry R , et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003; 124 (5) 1946-1955
  • 55 Xiao Y, Papiez L, Paulus R , et al. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009; 73 (4) 1235-1242
  • 56 Fakiris AJ, McGarry RC, Yiannoutsos CT , et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009; 75 (3) 677-682
  • 57 Onishi H, Shirato H, Nagata Y , et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?. Int J Radiat Oncol Biol Phys 2011; 81 (5) 1352-1358
  • 58 Grutters JP, Kessels AG, Pijls-Johannesma M, De Ruysscher D, Joore MA, Lambin P. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol 2010; 95 (1) 32-40
  • 59 Timmerman R, Paulus R, Galvin J , et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303 (11) 1070-1076
  • 60 Timmerman RD, Hu C, Michalski J , et al. Long-term Results of RTOG 0236: A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Medically Inoperable Stage I Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2014; 90 (1) S30
  • 61 Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol 2012; 13 (8) 802-809
  • 62 Nanda RH, Liu Y, Gillespie TW , et al. Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: A National Cancer Data Base analysis. Cancer 2015; 121 (23) 4222-4230
  • 63 Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 2010; 28 (35) 5153-5159
  • 64 Haasbeek CJ, Palma D, Visser O, Lagerwaard FJ, Slotman B, Senan S. Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol 2012; 23 (10) 2743-2747
  • 65 Shirvani SM, Jiang J, Chang JY , et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 2012; 84 (5) 1060-1070
  • 66 Stephans KL, Djemil T, Reddy CA , et al. Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol 2009; 4 (7) 838-844
  • 67 Henderson M, McGarry R, Yiannoutsos C , et al. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008; 72 (2) 404-409
  • 68 Miyamoto T, Baba M, Yamamoto N , et al; Working Group for Lung Cancer. Curative treatment of Stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen. Int J Radiat Oncol Biol Phys 2007; 67 (3) 750-758
  • 69 Baumann P, Nyman J, Hoyer M , et al. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol 2008; 88 (3) 359-367
  • 70 Guckenberger M, Klement RJ, Kestin LL , et al. Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2013; 85 (4) 1074-1081
  • 71 Stanic S, Paulus R, Timmerman RD , et al. No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys 2014; 88 (5) 1092-1099
  • 72 Linda A, Trovo M, Bradley JD. Radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes. Eur J Radiol 2011; 79 (1) 147-154
  • 73 Choi YW, Munden RF, Erasmus JJ , et al. Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis. Radiographics 2004; 24 (4) 985-997 , discussion 998
  • 74 Kimura T, Matsuura K, Murakami Y , et al. CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers?. Int J Radiat Oncol Biol Phys 2006; 66 (2) 483-491
  • 75 Hübner RH, Gitter W, El Mokhtari NE , et al. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques 2008; 44 (4) 507-511 , 514–517
  • 76 Ghobadi G, Hogeweg LE, Faber H , et al. Quantifying local radiation-induced lung damage from computed tomography. Int J Radiat Oncol Biol Phys 2010; 76 (2) 548-556
  • 77 Dunlap NE, Yang W, McIntosh A , et al. Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass-like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2012; 84 (5) 1071-1077
  • 78 Eisenhauer EA, Therasse P, Bogaerts J , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (2) 228-247
  • 79 Trovo M, Linda A, El Naqa I, Javidan-Nejad C, Bradley J. Early and late lung radiographic injury following stereotactic body radiation therapy (SBRT). Lung Cancer 2010; 69 (1) 77-85
  • 80 Guckenberger M, Heilman K, Wulf J, Mueller G, Beckmann G, Flentje M. Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. Radiother Oncol 2007; 85 (3) 435-442
  • 81 Faruqi S, Giuliani ME, Raziee H , et al. Interrater reliability of the categorization of late radiographic changes after lung stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2014; 89 (5) 1076-1083
  • 82 Kishan AU, Wang PC, Sheng K , et al. Correlation of clinical and dosimetric parameters with radiographic lung injury following stereotactic body radiotherapy. Technol Cancer Res Treat 2015; 14 (4) 411-418
  • 83 Takeda A, Kunieda E, Takeda T , et al. Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 2008; 70 (4) 1057-1065
  • 84 Matsuo Y, Nagata Y, Mizowaki T , et al. Evaluation of mass-like consolidation after stereotactic body radiation therapy for lung tumors. Int J Clin Oncol 2007; 12 (5) 356-362
  • 85 Aoki T, Nagata Y, Negoro Y , et al. Evaluation of lung injury after three-dimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance. Radiology 2004; 230 (1) 101-108
  • 86 Kyas I, Hof H, Debus J, Schlegel W, Karger CP. Prediction of radiation-induced changes in the lung after stereotactic body radiation therapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007; 67 (3) 768-774
  • 87 Palma DA, van Sörnsen de Koste J, Verbakel WF, Vincent A, Senan S. Lung density changes after stereotactic radiotherapy: a quantitative analysis in 50 patients. Int J Radiat Oncol Biol Phys 2011; 81 (4) 974-978
  • 88 Hof H, Zgoda J, Nill S , et al. Time- and dose-dependency of radiographic normal tissue changes of the lung after stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 2010; 77 (5) 1369-1374
  • 89 Diot Q, Kavanagh B, Schefter T, Gaspar L, Stuhr K, Miften M. Regional normal lung tissue density changes in patients treated with stereotactic body radiation therapy for lung tumors. Int J Radiat Oncol Biol Phys 2012; 84 (4) 1024-1030
  • 90 Vinogradskiy Y, Diot Q, Kavanagh B, Schefter T, Gaspar L, Miften M. Spatial and dose-response analysis of fibrotic lung changes after stereotactic body radiation therapy. Med Phys 2013; 40 (8) 081712
  • 91 Yu V, Kishan AU, Cao M, Low D, Lee P, Ruan D. Dose impact in radiographic lung injury following lung SBRT: statistical analysis and geometric interpretation. Med Phys 2014; 41 (3) 031701
  • 92 Videtic GM, Hu C, Singh AK , et al. A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys 2015; 93 (4) 757-764
  • 93 Timmerman R, McGarry R, Yiannoutsos C , et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006; 24 (30) 4833-4839
  • 94 Song SY, Choi W, Shin SS , et al. Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer 2009; 66 (1) 89-93
  • 95 Milano MT, Chen Y, Katz AW, Philip A, Schell MC, Okunieff P. Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy. Radiother Oncol 2009; 91 (3) 301-306
  • 96 Corradetti MN, Haas AR, Rengan R. Central-airway necrosis after stereotactic body-radiation therapy. N Engl J Med 2012; 366 (24) 2327-2329
  • 97 Chang JY, Balter PA, Dong L , et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008; 72 (4) 967-971
  • 98 Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol 2011; 6 (12) 2036-2043
  • 99 Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Stereotactic body radiotherapy for central lung tumors. J Thorac Oncol 2012; 7 (9) 1394-1399
  • 100 Nuyttens JJ, van der Voort van Zyp NC, Praag J , et al. Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors. Radiother Oncol 2012; 102 (3) 383-387
  • 101 Chang JY, Li QQ, Xu QY , et al. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “no fly zone”. Int J Radiat Oncol Biol Phys 2014; 88 (5) 1120-1128
  • 102 Chang JY, Bezjak A, Mornex F ; IASLC Advanced Radiation Technology Committee. Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned. J Thorac Oncol 2015; 10 (4) 577-585
  • 103 Roesch J, Andratschke N, Guckenberger M. SBRT in operable early stage lung cancer patients. Transl Lung Cancer Res 2014; 3 (4) 212-224
  • 104 Soldà F, Lodge M, Ashley S, Whitington A, Goldstraw P, Brada M. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort. Radiother Oncol 2013; 109 (1) 1-7
  • 105 Nagata Y, Hiraoka M, Shibata T , et al. Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403. Int J Radiat Oncol Biol Phys 2015; 93 (5) 989-996
  • 106 Asamura H, Goya T, Koshiishi Y , et al; Japanese Joint Committee of Lung Cancer Registry. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 2008; 3 (1) 46-52
  • 107 Matsuoka H, Okada M, Sakamoto T, Tsubota N. Complications and outcomes after pulmonary resection for cancer in patients 80 to 89 years of age. Eur J Cardiothorac Surg 2005; 28 (3) 380-383
  • 108 Shirvani SM, Jiang J, Chang JY , et al. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg 2014; 149 (12) 1244-1253
  • 109 Chang JY, Senan S, Paul MA , et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 2015; 16 (6) 630-637
  • 110 Pignon JP, Tribodet H, Scagliotti GV , et al; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26 (21) 3552-3559
  • 111 Strauss GM, Herndon II JE, Maddaus MA , et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26 (31) 5043-5051
  • 112 Burdett S, Pignon JP, Tierney J , et al; Non-Small Cell Lung Cancer Collaborative Group. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev 2015; 3 (3) CD011430
  • 113 Garon EB. Current perspectives in immunotherapy for non-small cell lung cancer. Semin Oncol 2015; 42 (Suppl. 02) S11-S18
  • 114 Minguet J, Smith KH, Bramlage P. Targeted therapies for treatment of non-small cell lung cancer-recent advances and future perspectives. Int J Cancer 2016; 138 (11) 2549-2561
  • 115 Simone II CB, Burri SH, Heinzerling JH. Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. Transl Lung Cancer Res 2015; 4 (5) 545-552